CTLA4 and urothelial carcinoma: Corradi et al. showed very interesting results for the combination with anti-CTLA4 immunotherapy in a heterotopic urothelial carcinoma mouse model: significantly reduced tumor growth, reduced development of lung metastases, prolonged survival, and no tumor growth after tumor re-irradiation in pretreated mice [42].